Biocon to merge biologics unit in $5.5 billion deal | India News
Kiran Mazumdar-Shaw said the combined entity would position Biocon among the few global players with scale in both generics and biologics NEW DELHI: Biocon will fully integrate its biosimilars arm, Biocon Biologics into the parent, in a deal valuing the unit at $5.5 billion.The move is aimed at creating a unified biopharma powerhouse, and to…